The Spectacular Rookie Venture Company

The sustained-release post-operative pain treatment has been confirmed to provide pain relief lasting for more than 3 days.

G2GBio, a company founded six years ago, has received approval for Phase 1 clinical trials of its sustained-release post-operative pain treatment.

G2GBIO possess long-acting formulation technology and is aiming for commercialization.

The development of post-operative pain treatment with analgesic effects lasting for more than 3 days has entered the commercialization clinical phase.

This medication, as a non-narcotic analgesic, is expected to be a potential replacement for traditional narcotic pain treatment.

According to the South Korean Ministry of Food and Drug Safety, G2GBio received approval for Phase 1 clinical trials of ‘GB-6002’ on the 21st.

Both domestically and internationally, there is a strong focus on developing non-narcotic pain treatments as alternatives to highly addictive and side-effect-prone narcotic pain treatments. However, it is noteworthy that this young biotech venture, founded six years ago, is taking the lead in the challenge of commercialization.

The product under development by G2GBio (GB6002) is an extended-release pain reliever, significantly increasing the duration of pain relief compared to existing products.

API chosen by G2GBio is 'Ropivacaine', a non-narcotic pain reliever.

In South Korea, narcotic pain relievers are commonly used to manage post-operative pain.

The most commonly used narcotic pain relievers in South Korea belong to the opioid class and include substances such as morphine, fentanyl, codeine, oxycodone, and tramadol, which are opioid analogs.

Narcotic pain relievers have been associated with serious drug dependence and addiction side effects. In the United States, there have been reports that over the past 20 years, approximately 700,000 people have died due to drug misuse and abuse.

Ropivacaine, one of the non-narcotic pain relievers, is known for its lower toxicity to the cardiovascular and central nervous systems, making it a safer pharmaceutical option. Additionally, it has the potential to be effective in post-operative pain management by selectively blocking sensory nerves rather than motor nerves.

The company stated, "GB-6002 is a sustained-release injectable formulation designed to be administered directly to the surgical site, reducing systemic exposure to the drug compared to conventional administration methods. Our goal is to minimize side effects compared to traditional methods and provide pain relief for over 3 days with a single administration."

If the effect lasts for more than 3 days, it significantly enhances the convenience for both patients and healthcare providers when it comes to pain medication administration.

This is because the duration of pain relief provided by the pain medication is only a few hours, and as a result, patients need to administer the medication whenever their pain becomes severe. This process requires careful consideration of factors such as the dosage and timing of each dose.

Considering that the typical duration of post-operative pain ranges from 2 to 7 days, the development of sustained-release pain relievers can significantly reduce the frequency of administration compared to conventional methods.

With its specialized expertise in the development of long-acting formulations, G2GBio is garnering expectations for the commercialization of sustained-release non-narcotic pain relievers.

G2GBio, established just six years ago, has gained recognition as a technologically advanced bioventure company, having registered 34 patents, including 27 international patents. They also have a remarkable 67 patent applications currently in progress.

Among the long-acting products developed by the company, there is a clinical-stage product: an injectable containing the active ingredient donepezil, which maintains its effectiveness for one month.

In addition to that, the company is also developing long-acting treatments for diabetes, osteoarthritis, prostate cancer, Androgenic alopecia, and hepatitis B, significantly extending the duration of effectiveness for these therapies.